Manufacturing Cell Therapies Using Engineered Biomaterials

Trends Biotechnol. 2017 Oct;35(10):971-982. doi: 10.1016/j.tibtech.2017.06.008. Epub 2017 Jul 12.


Emerging manufacturing processes to generate regenerative advanced therapies can involve extensive genomic and/or epigenomic manipulation of autologous or allogeneic cells. These cell engineering processes need to be carefully controlled and standardized to maximize safety and efficacy in clinical trials. Engineered biomaterials with smart and tunable properties offer an intriguing tool to provide or deliver cues to retain stemness, direct differentiation, promote reprogramming, manipulate the genome, or select functional phenotypes. This review discusses the use of engineered biomaterials to control human cell manufacturing. Future work exploiting engineered biomaterials has the potential to generate manufacturing processes that produce standardized cells with well-defined critical quality attributes appropriate for clinical testing.

Keywords: biomanufacturing; biomaterials; cell therapies; gene editing; immunotherapy; regenerative medicine; reprogramming; stem cells.

Publication types

  • Review
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biocompatible Materials / chemistry
  • Biocompatible Materials / therapeutic use*
  • Cell Engineering / instrumentation
  • Cell Engineering / methods*
  • Cell- and Tissue-Based Therapy / instrumentation
  • Cell- and Tissue-Based Therapy / methods*
  • Clinical Trials as Topic
  • Humans


  • Biocompatible Materials